Jacquin C. Niles

ArticleVolume 45, Issue 7117664Open access Affiliations & Notes 1Division of Biological Sciences, University of California, La Jolla, San Diego, CA, USA 2Department of Pediatrics, University of California, San Diego, San Diego School of Medicine, La Jolla, San Diego, CA, USA 3Infectious Disease and Microbiome Program, The Broad Institute, Cambridge, MA, USA 4Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA 5Department of Microbiology...

Abstract Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold.

Sources of compounds and parasite lines and culturing MMV019719, MMV665924, and MMV897615 were freely available as part of the Medicines for Malaria Venture’s (MMV) Malaria Box. Triacsin C was purchased from Sigma-Aldrich (St. Louis, MO, ref. T4540). The 3D7 P. falciparum strain was originally obtained through MR4 as part of the BEI Resources Repository, NIAID, NIH: 3D7, MRA-102, deposited by D. J. Carucci.